Study
| Multicentre, single-arm, phase 2 trial (MARBLE) |
| Patients with advanced or recurrent thymic carcinoma, no prior systemic therapy |
| Atezolizumab + carboplatin + paclitaxel every 3 wks up to 6 cycles, followed by atezolizumab maintenance |
Efficacy
| ORR: 56% (ICR) |
| DCR: 98% |
| mPFS: 9.6 mos (ICR) [7.7–14.8] |
| mOS: NR [19.2–NE] |
| mDoR: 6.4 mos [4.1–NE] |
| PFS @6 mos: 75.0% [60.2–85.0] |
| PFS @12 mos: 43.3% [29.1–56.8] |
| OS @6 mos: 100% |
| OS @12 mos: 91.3% [67.3–94.6] |
Safety
| Grade ≥3 AEs: Neutropenia (56%), leukopenia (33%), febrile neutropenia (23%), rash (13%) |
| Immune-related AEs: Grade 3-4 skin disorders (17%), hepatitis (8%) |
| Peripheral sensory neuropathy (any grade): 88% |
| Treatment-related discontinuations: 6 pts |
| Treatment-related deaths: 0 |
Lancet Oncol 2025;26:331-42
http://doi.org/10.1016/S1470-2045(24)00710-7
Reviewed by Ulas D. Bayraktar, MD on Apr 7, 2025
